Alkermes reports positive phase I study results on MS drug
Alkermes, PLC, said on Monday that it has produced positive results from a phase one, randomized, double-blind clinical study of ALKS 8700, an oral monomethyl fumarate (MMF) molecule in development as a multiple sclerosis (MS) treatment. Read More »